
简介:
- 作者: Quan Zhou, Hongfei Li, Dario Gerace, Igor Nikolskly, Xi Wang, Jennifer Kenty-Ryu, Jingping Zhang, Matthew Hinderhofer, Elaine Robinson and Douglas A. Melton
- 杂志: BioRxiv
- Doi: https://www.doi.org/10.1101/2022.09.15.508091
- 出版日期: 2022 Sep 17
论文中使用的产品/服务
Quotation shows PackGene:ssAAV plasmids encoding Firefly luciferase (Luc2) (control) and Luc2-IL2N88D-TGFβ (experimental) (Fig. 6A) were packaged in AAV8-Y447F+Y773F(39) (PackGene) and injected i.p. into 4-week-old female NOD mice (n=10/group) (Jackson Laboratories) at a concentration of 5x10^11 GC/mouse.
Research Field:diabetes
AAV Serotype:AAV8
Animal or cell line strain:4-week-old female NOD mice
摘要
Transplanting human stem cell-derived islets (SC-islets) is a promising therapy for insulin-dependent diabetes. While functional SC-islets have been produced for clinical application, immune rejection by the host remains a challenge. Present attempts, including chronic immunosuppression and/or physical encapsulation, have some disadvantages. Here we explore a strategy to induce an immune-tolerant environment based on the immune privilege observed in the male gonad. Sperm appears after the maturation of the immune system and development of systemic self-tolerance and the testis protects these autoreactive germ cells by the physical structure of blood-testis-barrier (BTB) and active local immunosuppression. Human SC-islets transplanted into the mouse testis can be physically protected by the BTB and we find that the testis secretes cytokines that induce a population of regulatory T cells (Tregs) that express both CD4 and CD8. We identified cytokines secreted by testis and used a cocktail of IL-2, IL-10, and TGF-β for in vitro co-culture and in vivo transplantation demonstrating improved survival of SC-islets and the induction of Tregs.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
